Download PDF
Fortschr Neurol Psychiatr 2018; 86(12): 754-762
DOI: 10.1055/a-0644-2578
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

„Lithium in der Behandlung der Altersdepression. Was spricht dafür, was dagegen?“

„Lithium in the treatment of old age depression. What are the pros and cons?“
Sina Stühler
1   Charité Universitätsmedizin Berlin Campus Benjamin Franklin
,
Arnim Quante
1   Charité Universitätsmedizin Berlin Campus Benjamin Franklin
2   Psychiatry and Psychotherapy Friedrich von Bodelschwingh- Klinik, Klinik für Psychiatrie und Psychotherapie
› Author Affiliations
Further Information

Publication History

eingereicht 03 April 2018

akzeptiert 15 June 2018

Publication Date:
07 January 2019 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Anliegen Die Lithiumaugmentation ist eine der Behandlungsoptionen bei therapieresistenter Depression. In diesem Review soll die Studienlage zu der Anwendung von Lithium im höheren Lebensalter bei unipolarer Depression zusammengefasst werden.

Methode Es wurde eine selektive Literaturrecherche in PubMed durchgeführt. Es konnten insgesamt 15 relevante Artikel (Plazebokontrollierte Studien und Übersichtsarbeiten) miteinbezogen werden. Ergebnisse: Sowohl die klinischen Studien als auch die Reviews sprechen sich positiv für die Lithiumaugmentation im Alter aus. Die Remissionsraten und das Ansprechen auf das Lithium allgemein sind sehr hoch. Nierenschäden als gefürchtete Nebenwirkungen treten nur selten auf. Auch über längere Anwendung hinaus zeigt sich das Lithium als wirksam und verträglich, wobei Laborkontrollen engmaschiger durchgeführt werden sollten.

Schlussfolgerung Lithium präsentiert sich als wirksames Medikament bei therapieresistenter unipolaren Altersdepression. Im klinischen Alltag ist der Einsatz bei fehlender Kontraindikation zu empfehlen.

Abstract

Objective Augmentation with lithium is one of the treatment options in therapy-resistant depression. This review presents the current data concerning the use of lithium in elderly patients with unipolar depression.

Method Through a selective literature search in the database PubMed, 15 relevant articles were identified and included.

Results Both the clinical trials and reviews report in favor of lithium augmentation in elderly patients. Remission rates and response rates are high. Kidney damage, a feared side effect, is rarely seen. Even over longer periods of use, lithium is effective; however, close monitoring under laboratory tests must be carried out.

Conclusion Lithium represents an effective drug in the treatment of unipolar old age depression. Its use in daily clinical practice is therefore highly recommended.

Schlüsselwörter

Altersdepression - Lithium - Depression - Augmentation

Key words

Old age depression - Lithium - Depression - Augmentation
 

  • Literatur

  • 1 Blazer D. Depression in Late Life: Review and Commentary.Depression in late life: review and commentary. J Gerontol A Biol Sci Med Sci. 2003; 58 (03) : 249-65
    PubMedGoogle Scholar
  • 2 Notzon S, Alferunk J, Arolt V. Altersdepression Pathophysiologie, Diagnostik und Therapie. Nervenarzt 2016; · 87: 1017-1029
    CrossrefPubMedGoogle Scholar
  • 3 Terhürne G, Waldmann C. Depression und Suizidalität im Alter. Im Internet: www.kompetenznetzwerkgb.de/wpcontent/uploads/2017/03/Info_Depression_2015.pdf ; Stand: 15.12.2017
    PubMed
  • 4 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). S3-Leitlinie / Nationale Versorgungs-Leitlinie Unipolare Depression ( 2015 ). Im Internet: www.awmf.org/uploads/tx_szleitlinien/nvl005l_S3_Unipolare_Depression_2017-05.pdf; Stand: 15.12.2017
    PubMed
  • 5 Sproule B, Hardy B, Shulman K. Differential Pharmacokinetics of Lithium in Elderly Patients. Drugs & Aging 2000; 16 (03) : 165-177
    CrossrefPubMedGoogle Scholar
  • 6 De Carlo V, Calati R, Serretti A. Socio-demographic and clinical predictors of non-response / non-remission in treatment resistant depressed patients: A systematic review. Psychiatry Res 2016; 240: 421-430 . doi: 10.1016 / j.psychres.2016.04.034. Epub 2016 May 5.
    CrossrefPubMedGoogle Scholar
  • 7 Lenze EJ, Mulsant BH, Blumberger DM. et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. The Lancet 2015; 386: 2404-2412
    CrossrefPubMedGoogle Scholar
  • 8 Holthoff V. Pharmakotherapie der Altersdepression. Z Gerontol Geriat 2013; 46: 112-119
    CrossrefPubMedGoogle Scholar
  • 9 Coppen A. Lithium in Unipolar Depression and the Prevention of Suicide. J Clin Psychiatry 2000; 61 (suppl 9): 52-56
    PubMedGoogle Scholar
  • 10 Young AH. Lithium for long-term treatment of unipolar depression. Lancet Psychiatry 2017; 4 (07) : 511-512
    CrossrefPubMedGoogle Scholar
  • 11 Lepkifker E, Iancu I, Horesh N. et al. Lithium therapy for unipolar and bipolar depression among the middle-aged and older adult patient subpopulation. Depress Anxiety 2007; 24: 571-576
    CrossrefPubMedGoogle Scholar
  • 12 Fahy S, Lawlor BA. Discontinuation of lithium augmentation in an elderly cohort. Int J Geriatr Psychiatry 2001; 16: 1004-1009
    CrossrefPubMedGoogle Scholar
  • 13 Kok RM, Nolen WA, Heeren TJ. Outcome of late-life depression after 3 years of sequential treatment. Acta Psychiatr Scand 2009; 119: 274-281
    CrossrefPubMedGoogle Scholar
  • 14 Kok RM, Vink D, Heeren TJ. et al. Lithium Augmentation Compared With Phenelzine in Treatment-Resistant Depression in the Elderly: An Open, Randomized, Controlled Trial. J Clin Psychiatry 2007; 68 (08) : 1177-85
    CrossrefPubMedGoogle Scholar
  • 15 Wilkinson D, Holmes C, Woolford J. et al. Prophylactic therapy with lithium in elderly patients with Unipolar Major Depression. Int J Geriatr Psychiatry 2002; 17: 619-622
    CrossrefPubMedGoogle Scholar
  • 16 Pruckner N, Holthoff-Detto V. Antidepressant pharmacotherapie in old age depression – a review and clinical approach. Eur J Clin Pharmacol 2017; 73: 661-667
    CrossrefPubMedGoogle Scholar
  • 17 Abou-Saleh MT, Müller-Oerlingshausen B, Copper AJ. Lithium in the episode and suicide prophylaxis and in augmenting strategies in patients with unipolar depression. Int J Bipolar Disord 2017; 5: 11
    CrossrefPubMedGoogle Scholar
  • 18 Bauer M, Adli M, Bschor T. et al. Lithium’s Emerging Role in the Treatment of Refractory Major Depressive Episodes: Augmentation of Antidepressants. Neuropsychobiology 2010; 62: 36-42
    CrossrefPubMedGoogle Scholar
  • 19 McKnight RF, Adida M, Budge K. et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379: 721-28
    CrossrefPubMedGoogle Scholar
  • 20 Gong R, Wang P, Dowrkin L. What we need to know about the effect of lithium on the kidney. Am J Physiol Renal Physiol 311: F1168-F1171 .
    PubMedGoogle Scholar
  • 21 Aprahamian I, Santos F, dos Santos B. et al. Long-Term, Low-Dose Lithium Treatment Does Not Impair Renal Function in the Elderly: A 2-Year Randomized, Placebo-Controlled Trial Followed by Single-Blind Extension. J Clin Psychiatry 2014; Jul; 75 (07) : e672-8
    CrossrefPubMedGoogle Scholar
  • 22 Lehmann SW, Lee J. Lithium-associated hypercalcemia and hyperparathyroidism in the elderly: What do we know?. J Affect Diord 2013; 146 , 151-157
    PubMedGoogle Scholar
  • 23 Aiff H, Attman PO, Aurell M. et al. Effects of 10 to 30 years of lithium treatment on kidney function. Journal Psychopharmacol 2015; , Vol. 29 (5) 608-614
    PubMedGoogle Scholar
  • 24 Gahr M, Freudenmann RW, Connemann BJ. et al. Nephrotoxizität und Langzeitbehandlung mit Lithium. Psychiat Prax 2014; 41: 15-22
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Hou L, Helbronner U, Degenhardt F. et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genom-wide association study. Lancet. 2016; 387 (10023): 1085-1093
    CrossrefPubMedGoogle Scholar
  • 26 Rej S, Beaulieu S, Segal M. et al. Lithium dosing and serum concentrations across the age spectrum: from early adulthood to the tenth decade of life. Drugs Aging 2014; 12: 911-6
    PubMedGoogle Scholar
  • 27 Alevizos B, Alevizos E, Leonardou A. et al. Low dosage lithium augmentation in venlaflexine resistant depression: an open-label study. Psychiatriki. 2012; 2: 143-8
    PubMedGoogle Scholar
  • 28 Clos S, Rauchhaus P, Severn A. et al. Long-term effect of lithium maintenance therapy on estimated glomerular filtration rate in patients with affective disorders: a population-based cohort study. Lancet Psychiatry 2015; 12: 1075-83
    PubMedGoogle Scholar
  • 29 Österreichische Gesellschaft für Neuropsychopharmakologie und Biologische Psychiatrie (ÖGPB). DFP-Literatur: Lithiumtherapie bei bipolarer Störung. Im Internet: oegpb.at/2014/09/03/dfp-literatur-lithiumtherapie-bei-bipolarer-stoerung; Stand: 16.12.2017
    PubMed
  • 30 Gitlin M. Lithium side effects and toxicity: prevalence and managment strategies. Int J Bipolar Disorder 2016; 1: 27
    PubMedGoogle Scholar
  • 31 Shane E, Irani D. Hypercalcemia: Pathogenesis, clinical manifestations, differential diagnosis, and management. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. , 6, Favus MJ. (Ed), American Society for Bone and Mineral Research; , Washington, DC: 2006
    Google Scholar
  • 32 Prosser JM, Fieve RR. Patients receiving lithium therapy have a reduced prevalence of neurological and cardiovascular disorders. Prog Neuropsychopharmacol Biol Psychiatry 2016; 71: 39-44
    CrossrefPubMedGoogle Scholar
  • 33 Fiorentini A, Rosi MC, Grossi C. et al. Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice. PLoS One 2010; 12: e14382
    PubMedGoogle Scholar
  • 34 Cheng C, Zandi P, Stuart E. et al. Association Between Lithium Use and Risk of Alzheimer’s Disease. J Clin Psychiatry 2017; 78 (02) : e139-e145
    CrossrefPubMedGoogle Scholar
  • 35 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen. ( 2012 .) Im Internet: www.awmf.org/uploads/tx_szleitlinien/038-019l_S3_Bipolare_Stoerungen_2012-09-abgelaufen.pdf; Stand: 15.12.2017
    PubMedGoogle Scholar
  • 36 Lindström L, Lindström E, Nilsson M. et al. Maintenance therapy with second generation antipsychotics for bipolar disorder – A systematic review and meta-analysis. J Affect Disord 2017; 213: 138-150 . doi: 10.1016 / j.jad.2017.02.012. (Epub 2017 Feb 14.).
    CrossrefPubMedGoogle Scholar
  • 37 Kim A, Lim S, Lee H. et al. A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. Int Clin Psychopharmaco 2016; 31 (04) : 210-7
    PubMedGoogle Scholar
  • 38 Köhler S, Stöver LA, Bschor T. MAO-Hemmer als Behandlungsoption der therapieresistenten Depression: Anwendung, Wirksamkeit und Besonderheiten. Fortschr Neurol Psychiatr 2014; 82: 228-36
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Bschor T, Bauer M, Adli M. Chronische und therapieresistente Depression. Dtsch Arztebl Int 2014; 111 (45) : 766-76
    PubMedGoogle Scholar
  • 40 Sackeim HA, Haskett RF, Mulsant BH. et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 2001; 285: 1299-1307
    CrossrefPubMedGoogle Scholar
  • 41 Blumberger DM, Hsu JH, Daskalaskis ZJ. A Review of Brain Stimulation Treatments for Late-Life Depression. Curr Treat Options Psychiatry 2015; 4: 413-421
    PubMedGoogle Scholar
  • 42 Cipriani A, Smith K, Burgess S. et al. Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. Cochrane Database Syst Rev 2006 (04) : CD003492
    PubMedGoogle Scholar
  • 43 Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychipharmacol. 1999; 5: 427-34
    PubMedGoogle Scholar